Mineralys Therapeutics, Inc. (MLYS)
| Market Cap | 353.50M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -56.58M |
| Shares Out | 41.11M |
| EPS (ttm) | -3.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 139,264 |
| Open | 8.48 |
| Previous Close | 8.57 |
| Day's Range | 8.31 - 8.75 |
| 52-Week Range | 5.85 - 21.98 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 36.00 (+318.61%) |
| Earnings Date | Feb 13, 2024 |
About MLYS
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for MLYS stock is "Strong Buy." The 12-month stock price forecast is $36.0, which is an increase of 318.61% from the latest price.
News
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
– Topline data from confirmatory Launch-HTN trial expected in 2H 2025 – – Topline data from ongoing Advance-HTN pivotal trial expected in 2H 2024 – RADNOR, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Miner...
Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023
– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of positive feedback loop linking obesity, leptin and aldosterone –
Mineralys Therapeutics to Participate in Three Upcoming Conferences
RADNOR, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic k...
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
– On track to initiate planned Phase 3 pivotal Launch-HTN trial of lorundrostat to treat patients with uncontrolled or resistant hypertension in 2H 2023 –
Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting
– Analysis further supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in patients with uncontrolled or treatment-resistant hy...
Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023
RADNOR, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic k...
Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023
Late-breaking poster presentation at ASN's Kidney Week 2023 - - - Poster presentation at AHA's Scientific Sessions 2023
Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas
RADNOR, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...
Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023
RADNOR, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...
Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension
– Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure (BP) with a well-tolerated profile –
Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions
– Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure (BP), including an enhanced response in individuals with eleva...
Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions
RADNOR, Pa., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...
Mineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023
RADNOR, Pa., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abno...
Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
– Continue enrolling subjects in ongoing pivotal Advance-HTN trial of lorundrostat, for the treatment of patients with uncontrolled or resistant hypertension –
Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023
RADNOR, Pa., July 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abno...
Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)
– Plan to initiate a Phase 2 proof of concept trial of lorundrostat alone and in combination with an SGLT2 inhibitor for CKD in the second half of 2023 –
Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference
RADNOR, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnor...
Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
– Commenced patient dosing in lorundrostat pivotal clinical program, for the treatment of patients with uncontrolled or resistant hypertension in April 2023 –
Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension
– Topline data from the trial are expected in the first half of 2024 – – A second, pivotal trial of lorundrostat in uncontrolled and resistant hypertension expected to commence enrollment in the secon...
Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023
RADNOR, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnor...
Mineralys Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference on Wednesday, May 10, 2023
RADNOR, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abn...
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
– Lorundrostat pivotal clinical program, for the treatment of patients with uncontrolled hypertension, expected to begin in the first half of 2023 –
Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC
Lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension
Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023
RADNOR, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abn...
Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023
RADNOR, Pa., Feb. 20, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abno...